Shots:

• Generium is the first company to develop biosimilar of Dornase Alfa which received approval as an inhalation solution to be used together with antibiotics- bronchodilators- and steroids for controlling symptoms of cystic fibrosis
• The biosimilar of Dornase Alfa is the sixth product to be approved utilizing Selexis’ SUREtechnology Platform and will be available to maintain the QoL in patients with cystic fibrosis
• Selexis’ SUREtechnology Platform is based on Selexis Genetic Elements- a novel human DNA based elements controlling the dynamic organization of chromatin across mammalian cells and improves the way cells are used in the discovery- development and manufacturing of recombinant proteins

Click here to­ read full press release/ article | Ref: Selexis | Image: Chicago Tribune